日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical)

Lugano 分类在霍奇金淋巴瘤和非霍奇金淋巴瘤的初始评估、分期和疗效评估中的应用:PRoLoG 共识倡议(第 1 部分 - 临床)

Ricard, Fabien; Cheson, Bruce; Barrington, Sally; Trotman, Judith; Schmid, Annette; Brueggenwerth, Guenther; Salles, Gilles; Schwartz, Larry; Goldmacher, Greg; Jarecha, Rudresh; Narang, Jayant; Broussais, Florence; Galette, Paul; Liu, Min; Bajpai, Surabhi; Perlman, Eric; Gillis, Julie; Smalberg, Ira; Terve, Pierre; Zahlmann, Gudrun; Korn, Ron

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical)

Lugano 分类在霍奇金淋巴瘤和非霍奇金淋巴瘤的初始评估、分期和疗效评估中的应用:PRoLoG 共识倡议(第 2 部分 - 技术)

Ricard, Fabien; Barrington, Sally; Korn, Ron; Brueggenwerth, Guenther; Trotman, Judith; Cheson, Bruce; Salles, Gilles; Schwartz, Larry; Goldmacher, Greg; Jarecha, Rudresh; Narang, Jayant; Broussais, Florence; Galette, Paul; Liu, Min; Bajpai, Surabhi; Perlman, Eric; Gillis, Julie; Smalberg, Ira; Terve, Pierre; Zahlmann, Gudrun; Schmid, Annette

A novel read methodology to evaluate the optimal dose of (68)Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

一项评估 (68)Ga-satoreotide trizoxetan 作为 PET 显像剂在胃肠胰神经内分泌肿瘤患者中最佳剂量的新型读取方法:一项 II 期临床试验

Miller, Colin G; Grønbæk, Henning; Virgolini, Irene; Kjaer, Andreas; Terve, Pierre; Bahri, Shadfar; Iversen, Peter; Svirydenka, Hanna; Rohban, Thomas; McEwan, Sandy